Fintel reports that on January 30, 2025, Stifel upgraded their outlook for Edwards Lifesciences (XTRA:EWL) from Hold to Buy. As of January 28, 2025, the average one-year price target for Edwards ...
That said, past performance doesn't equal forward returns. There is a lot to like about EWL under the hood, with this fund basically offering investors quality international blue chip exposure at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback